Outbreak of Candida lusitaniae bloodstream infection in neonatal intensive care unit: case series
Main Article Content
Keywords
Candida lusitaniae, neonatal sepsis, NICU, outbreak, voriconazole
Abstract
Introduction: Neonatal sepsis remains a significant health challenge, particularly in low- and middle-income countries (LMICs), where inadequate healthcare infrastructure and sanitation contribute to its high incidence. Sepsis is defined as life-threatening organ dysfunction resulting from a dysregulated immune response to infection. Neonates are particularly vulnerable due to immature immune systems. Candida species, especially Candida albicans and Candida parapsilosis, are common pathogens, but Candida lusitaniae has also emerged as a notable cause of neonatal sepsis, with increased resistance to Amphotericin B. This case series highlights an outbreak of Candida lusitaniae bloodstream infections in a neonatal intensive care unit (NICU), emphasizing the diagnostic and management challenges of rare fungal infections.
Case Description: In this report, we describe five neonatal sepsis cases caused by Candida lusitaniae in our NICU. All patients exhibited respiratory distress, pneumonia, and elevated procalcitonin levels, and were treated with Voriconazole. The neonates had varying risk factors, including prematurity, low birth weight, and asphyxia. Blood cultures identified Candida lusitaniae in all cases, with susceptibility testing confirming sensitivity to Voriconazole, Amphotericin B, and Flucytosine. Environmental sampling revealed contamination in the NICU, specifically from a sink, suggesting nosocomial transmission. In response, the NICU was decontaminated, infection control protocols were reinforced, and environmental surveillance was intensified. All patients improved clinically and were discharged without major complications, except for mild encephalopathy in one case.
Conclusion: This outbreak underlines the importance of timely identification and appropriate therapy in managing rare fungal infections in neonates. It also highlights the critical role of environmental sources in nosocomial infections and the need for robust infection control measures in NICUs. Strict infection prevention strategies, including enhanced cleaning, staff training, and surveillance, are essential to preventing such outbreaks in high-risk settings.
References
2. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801.
3. Bethou A, Bhat BV. Neonatal Sepsis—Newer Insights. Indian J Pediatr. 2022;89(3):267–73.
4. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir Med. 2018;6(3):223–30.
5. Weimer KED, Smith PB, Puia-Dumitrescu M, Aleem S. Invasive fungal infections in neonates: a review. Pediatr Res. 2022;91(2):404–12.
6. Mendoza-Reyes DF, Gómez-Gaviria M, Mora-Montes HM. Candida lusitaniae: Biology, Pathogenicity, Virulence Factors, Diagnosis, and Treatment. Infect Drug Resist. 2022;Volume 15:5121–35.
7. Viudes A, Pemán J, Cantón E, Salavert M, Ubeda P, López-Ribot J, et al. Two Cases of Fungemia due to Candida lusitaniae and a Literature Review. European Journal of Clinical Microbiology and Infectious Diseases. 2002;21(4):294–9.
8. Yusef D, Shalakhti T, Awad S, Algharaibeh H, Khasawneh W. Clinical characteristics and epidemiology of sepsis in the neonatal intensive care unit in the era of multi-drug resistant organisms: A retrospective review. Pediatr Neonatol. 2018;59(1):35–41.
9. Ballot DE, Bosman N, Nana T, Ramdin T, Cooper PA. Background changing patterns of neonatal fungal sepsis in a developing country. J Trop Pediatr. 2013;59(6):460–4.
10. Sousa RA, Oliveira Diniz LM, Lapa Marinho FE, Rezende LG, Carellos EM, Maia de Castro Romanelli R. Risk factors for candidemia in neonates: Systematic review and meta-analysis. Journal of Neonatal Nursing. 2022;28(2):83–92.
11. Khan Z, Ahmad S, Al-Sweih N, Khan S, Joseph L. Candida lusitaniae in Kuwait: Prevalence, antifungal susceptibility and role in neonatal fungemia. PLoS One. 2019;14(3):e0213532.
12. Sanchez PJ, Cooper BH. Candida lusitaniae: sepsis and meningitis in a neonate. Pediatr Infect Dis J. 1987;6(8):758–9.
13. Yinnon AM, Woodin KA, Powell KR. Candida lusitaniae infection in the newborn. Pediatr Infect Dis J. 1992;11(10):878–80.
14. Oleinik E, Della-Latta P, Rinaldi M, Saiman L. Candida Lusitaniae Osteomyelitis in a Premature Infant. Am J Perinatol. 1993;10(04):313–5.
15. Favel A, Michel-Nguyen A, Peyron F, Martin C, Thomachot L, Datry A, et al. Colony morphology switching of Candida lusitaniae and acquisition of multidrug resistance during treatment of a renal infection in a newborn: case report and review of the literature. Diagn Microbiol Infect Dis. 2003;47(1):331–9.
16. Gautam MK, Li J. Neonatal Candida Lusitaniae Septicemia. Journal of Nepal Paediatric Society. 2014;34(2):160–2.
17. Hammoud MS, Al-Taiar A, Fouad M, Raina A, Khan Z. Persistent candidemia in neonatal care units: risk factors and clinical significance. International Journal of Infectious Diseases. 2013;17(8):e624–8.
18. Apsemidou A, Füller MA, Idelevich EA, Kurzai O, Tragiannidis A, Groll AH. Candida lusitaniae Breakthrough Fungemia in an Immuno-Compromised Adolescent: Case Report and Review of the Literature. Journal of Fungi. 2020;6(4):380.
19. Scott NE, Edwin Erayil S, Kline SE, Selmecki A. Rapid Evolution of Multidrug Resistance in a Candida lusitaniae Infection during Micafungin Monotherapy. Antimicrob Agents Chemother. 2023;67(8).
20. Asner SA, Giulieri S, Diezi M, Marchetti O, Sanglard D. Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy. Antimicrob Agents Chemother. 2015;59(12):7715–22.
21. Kooshki P, Rezaei-Matehkolaei A, Mahmoudabadi AZ. The patterns of colonization and antifungal susceptibility of Candida, isolated from preterm neonates in Khorramabad, South West of Iran. J Mycol Med. 2018;28(2):340–4.
22. Autmizguine J, Tan S, Cohen-Wolkowiez M, Cotten CM, Wiederhold N, Goldberg RN, et al. Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. Pediatric Infectious Disease Journal. 2018;37(9):923–9.
23. Silver C, Rostas S. Comprehensive drug utilization review in neonates: liposomal amphotericin B. Journal of Pharmacy and Pharmacology. 2018;70(3):328–34.
24. Chen Y-H, Cheng I-L, Lai C-C, Tang H-J. Echinocandins vs. amphotericin B against invasive candidiasis in children and neonates: A meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2019;53(6):789–94.
25. Tsekoura M, Ioannidou M, Pana Z-D, Haidich A-B, Antachopoulos C, Iosifidis E, et al. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children. Pediatric Infectious Disease Journal. 2019;38(1):42–9.
26. Anaraki MR, Nouri-Vaskeh M, Oskoei SA. Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis. Clin Exp Pediatr. 2021;64(4):172–9.